Porownywarka

Abaloparatide vs Oxytocin side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

AbaloparatideOxytocin

Udostępnij porównanie peptydów

Wlasciwosc	Abaloparatide	Oxytocin
Kategoria	Hormonalne	Hormonalne
Znany tez jako	Tymlos, BA058	Pitocin, Syntocinon, The Love Hormone
Zatwierdzony przez FDA	Tak	Tak
Status kliniczny	FDA approved for osteoporosis in postmenopausal women and in men at high fracture risk; the male indication was added in December 2022. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	FDA approved for labor and postpartum use; other uses remain under research Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Osteoporosis, bone health, fracture risk reduction	Social bonding, anxiety, trust, emotional wellbeing
Jak dziala	Abaloparatide is described as a PTHrP analog that engages the PTH type 1 receptor. Compared with teriparatide, the source reports a different receptor-binding profile, including preference for an RG-bound receptor state and a more transient signal. The proposed rationale is an anabolic bone effect through osteoblast-driven formation with less stimulation of resorption and calcium elevation than might occur with longer PTHR1 signaling.	Oxytocin acts through the oxytocin receptor, a G-protein-coupled receptor described in the source as present in the uterus, breast tissue, and multiple brain areas including the amygdala. In peripheral tissues, signaling is linked to calcium-mediated uterine contraction and milk ejection. Central effects are described as modulation of fear, reward, and social-attention circuitry, but intranasal research is difficult to interpret because the amount reaching the brain is uncertain and may involve indirect pathways.
Typowe dawkowanie	80 mcg daily · Once daily · Subcutaneous injection daily	10-24 IU intranasal as needed · As needed · Intranasal
Dawkowanie z badań	80 mcg subcutaneous daily · Once daily · Maximum 2 years · Subcutaneous injection daily	10-40 IU IV for labor · Single dose or short-term use · IV (obstetric); intranasal (research)
Typowy czas trwania	Maximum 2 years	Single dose or short-term use
Podanie	Subcutaneous injection daily	IV in obstetric labeling; intranasal in research contexts
Timing	Morning or as directed With or without food	As needed in studied social or bonding contexts With or without food
Poziom dowodów	Zatwierdzone przez FDA	Zatwierdzone przez FDA
Mozliwe skutki uboczne	Hypercalciuria (Source reports 11%.) Dizziness (Source reports 10%.) Nausea (Source reports 8%.) +4 więcej Palpitations (Source reports 5%.) Injection site reactions (Reported in the source without a percentage.) Orthostatic hypotension (Reported in the source without a percentage.) Osteosarcoma risk in rats (Source describes this as a rat safety signal associated with prior class labeling discussion.)	Headache Nausea and vomiting Uterine hypertonicity (Relevant to obstetric use and uterine activity.) +4 więcej Blood pressure changes Arrhythmias Water intoxication (Reported with prolonged use in the source.) Maternal and fetal complications (The source flags this risk in obstetric contexts.)
Podsumowanie researchu	The source highlights randomized clinical evidence from the ACTIVE phase 3 trial in more than 2,400 postmenopausal women, comparing abaloparatide with placebo and open-label teriparatide over 18 months. It reports substantial reductions versus placebo in new vertebral and nonvertebral fractures and a favorable comparison with teriparatide for major osteoporotic fractures in that dataset. It also notes cardiovascular safety analyses, transient heart-rate increases as an on-label class effect, and ATOM trial bone-density data that supported the later male osteoporosis indication.	The source treats injectable obstetric oxytocin as established, while describing intranasal behavioral research as contested. For social reward, a 2023 systematic review covering 19 randomized, double-blind, placebo-controlled studies and about 984 participants reported a clearer signal in brain-activity outcomes than in behavior or self-report. In autism research, the source cites a 2021 Scientific Reports randomized trial that did not find a substantial empathy-related neural activation change, and it notes that repeated-dose studies have ranged from modest social-behavior findings to no clear effect. Context and sex-specific differences are presented as important reasons the findings remain difficult to generalize. Short-term intranasal trial safety was described as reassuring, but the source does not establish a reliable clinical benefit for these investigational uses.
Referencje	PMCAbaloparatide reference supplied by source NCBI BookshelfAbaloparatide reference supplied by source +2 więcej HealioFDA approval for abaloparatide in men with osteoporosis at high fracture risk Radius HealthTymlos approval announcement for increasing bone density in men with osteoporosis at high fracture risk	Peptibase peptides Peptibase peptides +3 więcej Peptibase peptides Peptibase peptides Peptibase peptides
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Abaloparatide

Oxytocin

Kategoria

Hormonalne

Znany tez jako

Tymlos, BA058

Pitocin, Syntocinon, The Love Hormone

Zatwierdzony przez FDA

Tak

Status kliniczny

FDA approved for osteoporosis in postmenopausal women and in men at high fracture risk; the male indication was added in December 2022.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

FDA approved for labor and postpartum use; other uses remain under research

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Osteoporosis, bone health, fracture risk reduction

Social bonding, anxiety, trust, emotional wellbeing

Jak dziala

Abaloparatide is described as a PTHrP analog that engages the PTH type 1 receptor. Compared with teriparatide, the source reports a different receptor-binding profile, including preference for an RG-bound receptor state and a more transient signal. The proposed rationale is an anabolic bone effect through osteoblast-driven formation with less stimulation of resorption and calcium elevation than might occur with longer PTHR1 signaling.

Oxytocin acts through the oxytocin receptor, a G-protein-coupled receptor described in the source as present in the uterus, breast tissue, and multiple brain areas including the amygdala. In peripheral tissues, signaling is linked to calcium-mediated uterine contraction and milk ejection. Central effects are described as modulation of fear, reward, and social-attention circuitry, but intranasal research is difficult to interpret because the amount reaching the brain is uncertain and may involve indirect pathways.

Typowe dawkowanie

80 mcg daily · Once daily · Subcutaneous injection daily

10-24 IU intranasal as needed · As needed · Intranasal

Dawkowanie z badań

80 mcg subcutaneous daily · Once daily · Maximum 2 years · Subcutaneous injection daily

10-40 IU IV for labor · Single dose or short-term use · IV (obstetric); intranasal (research)

Typowy czas trwania

Maximum 2 years

Single dose or short-term use

Podanie

Subcutaneous injection daily

IV in obstetric labeling; intranasal in research contexts

Timing

Morning or as directed

With or without food

As needed in studied social or bonding contexts

With or without food

Poziom dowodów

Zatwierdzone przez FDA

Mozliwe skutki uboczne

Hypercalciuria (Source reports 11%.)
Dizziness (Source reports 10%.)
Nausea (Source reports 8%.)

+4 więcej

Palpitations (Source reports 5%.)
Injection site reactions (Reported in the source without a percentage.)
Orthostatic hypotension (Reported in the source without a percentage.)
Osteosarcoma risk in rats (Source describes this as a rat safety signal associated with prior class labeling discussion.)

Headache
Nausea and vomiting
Uterine hypertonicity (Relevant to obstetric use and uterine activity.)

+4 więcej

Blood pressure changes
Arrhythmias
Water intoxication (Reported with prolonged use in the source.)
Maternal and fetal complications (The source flags this risk in obstetric contexts.)

Podsumowanie researchu

The source highlights randomized clinical evidence from the ACTIVE phase 3 trial in more than 2,400 postmenopausal women, comparing abaloparatide with placebo and open-label teriparatide over 18 months. It reports substantial reductions versus placebo in new vertebral and nonvertebral fractures and a favorable comparison with teriparatide for major osteoporotic fractures in that dataset. It also notes cardiovascular safety analyses, transient heart-rate increases as an on-label class effect, and ATOM trial bone-density data that supported the later male osteoporosis indication.

The source treats injectable obstetric oxytocin as established, while describing intranasal behavioral research as contested. For social reward, a 2023 systematic review covering 19 randomized, double-blind, placebo-controlled studies and about 984 participants reported a clearer signal in brain-activity outcomes than in behavior or self-report. In autism research, the source cites a 2021 Scientific Reports randomized trial that did not find a substantial empathy-related neural activation change, and it notes that repeated-dose studies have ranged from modest social-behavior findings to no clear effect. Context and sex-specific differences are presented as important reasons the findings remain difficult to generalize. Short-term intranasal trial safety was described as reassuring, but the source does not establish a reliable clinical benefit for these investigational uses.

Referencje

PMCAbaloparatide reference supplied by source NCBI BookshelfAbaloparatide reference supplied by source

+2 więcej

HealioFDA approval for abaloparatide in men with osteoporosis at high fracture risk Radius HealthTymlos approval announcement for increasing bone density in men with osteoporosis at high fracture risk

Peptibase peptides Peptibase peptides

+3 więcej

Peptibase peptides Peptibase peptides Peptibase peptides

Pełny profil

Zobacz szczegóły